High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients
Open Access
- 19 November 2009
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (5), 465-475
- https://doi.org/10.1111/j.1432-2277.2009.01006.x
Abstract
Several clinical and experimental models have underlined the role of the CXCR3‐binding chemokines in the immune‐mediated kidney diseases. This study aimed to investigate the predictive value of measuring pretransplant CXCL9 levels for acute rejection (AR) onset and kidney transplantation outcome. Pretransplantation serum levels of CXCL9 were tested retrospectively in 252 kidney graft recipients, whose stratification in two groups according to CXCL9 levels (272.1 pg/ml) showed highly significant differences in 5‐year survival rates (97.7% vs. 73.3%; P < 0.001). Multivariate analysis demonstrated that among the analysed variables, CXCL9 [relative risk (RR) 11.708] and AR (RR 3.604) had the highest predictive power of graft loss. Accordingly, patients with AR (254.4 ± 22.1; P < 0.05) and, even more, those with anti‐thymoglobulin (ATG)‐treated AR also showed increased pretransplant serum CXCL9 levels (319.3 ± 28.1, P < 0.001). Moreover, CXCL9 expression and distribution were investigated in tissue specimens obtained from 10 patients affected by AR, and wide CXCL9 expression was detected not only in infiltrating inflammatory cells but also in vascular and tubular structures. Measurement of pretransplant serum CXCL9 levels might represent the tracking of a clinically useful parameter to identify subjects at high risk of AR and graft failure. These findings might be used for the individualization of immunosuppressive therapies.Keywords
This publication has 49 references indexed in Scilit:
- Monokine Induced by Interferon-γ (MIG/CXCL9) Is Derived from Both Donor and Recipient Sources during Rejection of Class II Major Histocompatibility Complex Disparate Skin AllograftsThe American Journal of Pathology, 2009
- CXCR3 Antagonism Impairs the Development of Donor-Reactive, IFN-γ-Producing Effectors and Prolongs Allograft SurvivalTransplantation, 2009
- CXCL9, but not CXCL10, Promotes CXCR3-Dependent Immune-Mediated Kidney DiseaseJournal of the American Society of Nephrology, 2008
- Organ-Specific Differences in the Function of MCP-1 and CXCR3 During Cardiac and Skin Allograft RejectionTransplantation, 2007
- What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulationsKidney International, 2005
- Rapamycin for Treatment of Chronic Allograft Nephropathy in Renal Transplant PatientsJournal of the American Society of Nephrology, 2005
- BasiliximabDrugs, 2003
- Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) αβ+CD8+ single-positive T cells, TCRγδ+ T cells, and natural killer–type cells in human thymusBlood, 2001
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantThe New England Journal of Medicine, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999